Diet-Derived Gallated Catechins Prevent TGF-β-Mediated Epithelial-Mesenchymal Transition, Cell Migration and Vasculogenic Mimicry in Chemosensitive ES-2 Ovarian Cancer Cells

References

• Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376–1388. doi:10.1016/S0140-6736(13)62146-7
   PubMed Web of Science ®Google Scholar
• Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, et al. Ovarian cancer statistics, 2018. CA: Cancer J Clinicians. 2018;68:284–296. doi:10.3322/caac.21456
   PubMed Web of Science ®Google Scholar
• Canadian Cancer Society. 2019. Survival statistics for ovarian cancer. Retrieved from: http://www.cancer.ca/en/cancer-information/cancer-type/ovarian/prognosis-and-survival/survival-statistics/?region=on.
   Google Scholar
• Karlsson MC, Gonzalez SF, Welin J, Fuxe J. Epithelial-mesenchymal transition in cancer metastasis through the lymphatic system. Mol Oncol. 2017;11(7):781–791. doi:10.1002/1878-0261.12092
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559–1564. doi:10.1126/science.1203543
   PubMed Web of Science ®Google Scholar
• Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol. 2003;4:657–665. doi:10.1038/nrm1175
   PubMed Web of Science ®Google Scholar
• Martin TA, Jiang WG. Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta. 2009;1788(4):872–891. doi:10.1016/j.bbamem.2008.11.005
   PubMed Web of Science ®Google Scholar
• Thierry JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–142. doi:10.1038/nrm1835
   PubMed Web of Science ®Google Scholar
• Tsuji T, Ibaragi S, Hu GF. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res. 2009;69(18):7135–7139. doi:10.1158/0008-5472.CAN-09-1618
   PubMed Web of Science ®Google Scholar
• Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147(2):275–292. doi:10.1016/j.cell.2011.09.024
   PubMed Web of Science ®Google Scholar
• Roche J. The epithelial-to-mesenchymal transition in cancer. Cancers. 2018;10(2):52. doi:10.3390/cancers10020052
   PubMed Web of Science ®Google Scholar
• Clarke DC, Liu X. Decoding the quantitative nature of TGF-beta/Smad signaling. Trends Cell Biol. 2008;18(9):430–442. doi:10.1016/j.tcb.2008.06.006
   PubMed Web of Science ®Google Scholar
• Miyazono K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad, Ser B. 2009;85(8):314–323. doi:10.2183/pjab.85.314
   PubMed Web of Science ®Google Scholar
• Liu Q, Qiao L, Liang N, Xie J, Zhang J, Deng G, Luo H, Zhang J. The relationship between vasculogenic mimicry and epithelial-mesenchymal transitions. J Cell Mol Med. 2016;20(9):1761–1769. doi:10.1111/jcmm.12851
   PubMed Web of Science ®Google Scholar
• Yang CS, Wang H, Chen JX, Zhang J. Effects of tea catechins on cancer signaling pathways. Enzymes. 2014;36:195–221. doi:10.1016/B978-0-12-802215-3.00010-0
   PubMedGoogle Scholar
• Negri A, Naponelli V, Rizzi F, Bettuzzi S. Molecular targets of epigallocatechin-gallate (EGCG): A special focus on signal transduction and cancer. Nutrients. 2018;10(12):1936. doi:10.3390/nu10121936
   PubMed Web of Science ®Google Scholar
• Rady I, Mohamed H, Rady M, Siddiqui IA, Mukhtar H. Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea. Egyptian J Basic Appl Sci. 2018;5(1):1–23. doi:10.1016/j.ejbas.2017.12.001
   Google Scholar
• Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP, Harrap KR. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer. 1989;59(4):527–534. doi:10.1038/bjc.1989.108
   PubMed Web of Science ®Google Scholar
• Djerir D, Iddir M, Bourgault S, Lamy S, Annabi B. Biophysical evidence for differential gallated green tea catechins binding to membrane type-1 matrix metalloproteinase and its interactors. Biophys Chem. 2018;234:34–41. doi:10.1016/j.bpc.2018.01.002
   PubMed Web of Science ®Google Scholar
• Annabi B, Lee Y-T, Turcotte S, Naud E, Desrosiers RR, Champagne M, Eliopoulos N, Galipeau J, Béliveau R. Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. Stem Cells. 2003;21(3):337–347. doi:10.1634/stemcells.21-3-337
   PubMed Web of Science ®Google Scholar
• Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol. 2009;11(11):1287–1296. doi:10.1038/ncb1973
   PubMed Web of Science ®Google Scholar
• Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009;19(2):156–172. doi:10.1038/cr.2009.5
   PubMed Web of Science ®Google Scholar
• Fuxe J, Vincent T, Garcia de Herreros A. Transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle. 2010;9(12):2363–2374. doi:10.4161/cc.9.12.12050
   PubMed Web of Science ®Google Scholar
• Najafi M, Ahmadi A, Mortezaee K. Extracellular-signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) signaling as a target for cancer therapy: An updated review. Cell Biol Int. 2019;43(11):1206–1222. doi:10.1002/cbin.11187
   PubMed Web of Science ®Google Scholar
• Ahmadi A, Najafi M, Farhood B, Mortezaee K. Transforming growth factor-β signaling: Tumorigenesis and targeting for cancer therapy. J Cell Physiol. 2019;234(8):12173–12187. doi:10.1002/jcp.27955
   PubMed Web of Science ®Google Scholar
• Zhang J, Qiao L, Liang N, Xie J, Luo H, Deng G, Zhang J. Vasculogenic mimicry and tumor metastasis. J Buon. 2016;21(3):533–541.
   PubMed Web of Science ®Google Scholar
• Liu W, Lv C, Zhang B, Zhou Q, Cao Z. MicroRNA-27b functions as a new inhibitor of ovarian cancer-mediated vasculogenic mimicry through suppression of VE-cadherin expression. RNA. 2017;23(7):1019–1027. doi:10.1261/rna.059592.116
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu P, Wang X, Mao H. Role of X‑linked inhibitor of apoptosis‑associated factor‑1 in vasculogenic mimicry in ovarian cancer. Mol Med Rep. 2017;16(1):325–330. doi:10.3892/mmr.2017.6597
   PubMed Web of Science ®Google Scholar
• van Staalduinen J, Baker D, Ten Dijke P, van Dam H. Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer? Oncogene. 2018;37(48):6195–6211. doi:10.1038/s41388-018-0378-x
   PubMed Web of Science ®Google Scholar
• Huang RY-J, Chung VY, Thiery JP. Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer. Curr Drug Targets. 2012;13(13):1649–1653. doi:10.2174/138945012803530044
   PubMed Web of Science ®Google Scholar
• Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer. 2012;12:91doi:10.1186/1471-2407-12-91
   PubMed Web of Science ®Google Scholar
• Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY, Bapat SA. Snail and Slug mediate radioresistance and chemoresistance by antagonizing p53‐mediated apoptosis and acquiring a stem‐like phenotype in ovarian cancer cells. Stem Cells. 2009;27(9):2059–2068. doi:10.1002/stem.154
   PubMed Web of Science ®Google Scholar
• Ouanouki A, Lamy S, Annabi B. Anthocyanidins inhibit epithelial-mesenchymal transition through a TGFβ/Smad2 signaling pathway in glioblastoma cells. Mol Carcinog. 2017;56(3):1088–1099. doi:10.1002/mc.22575
   PubMed Web of Science ®Google Scholar
• Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10(6):415–424. doi:10.1038/nrc2853
   PubMed Web of Science ®Google Scholar
• Drabsch Y, Dijke P. TGF-β signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev. 2012;31(3–4):553–568. doi:10.1007/s10555-012-9375-7
   PubMed Web of Science ®Google Scholar
• Pickup M, Novitskiy S, Moses HL. The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer. 2013;13(11):788–799. doi:10.1038/nrc3603
   PubMed Web of Science ®Google Scholar
• Anthony ML, Nair R, Sebastian P, Karunagaran D. Changes in expression, and/or mutations in TGF-beta receptors (TGF-beta RI and TGF-beta RII) and Smad 4 in human ovarian tumors. J Cancer Res Clin Oncol. 2010;136:351–361. doi:10.1007/s00432-009-0703-4
   PubMed Web of Science ®Google Scholar
• Xi L, Hu W, Meng L, Zhou J, Lu Y, et al. Dysregulation of the TGF-β postreceptor signaling pathway in cell lines derived from primary or metastatic ovarian cancer. J Huazhong Univ Sci Technol [Med Sci]. 2004;24:62–65. doi:10.1007/BF02830708
   PubMedGoogle Scholar
• Levy L, Hill CS. Smad4 dependency defines two classes of transforming growth factor-beta target genes and distinguishes TGF–induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol. 2005;25(18):8108–8125. doi:10.1128/MCB.25.18.8108-8125.2005
   PubMed Web of Science ®Google Scholar
• Tachibana H. Molecular basis for cancer chemoprevention by green tea polyphenol EGCG. Forum Nutr. 2009;61:156–169. doi:10.1159/000212748
   PubMed Web of Science ®Google Scholar
• van den Brûle FA, Berchuck A, Bast RC, Liu F-T, Gillet C, Sobel ME, Castronovo V. Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer. 1994;30(8):1096–1099. doi:10.1016/0959-8049(94)90464-2
   Web of Science ®Google Scholar
• van den Brûle FA, Castronovo V, Ménard S, Giavazzi R, Marzola M, Belotti D, Taraboletti G. Expression of the 67 kD laminin receptor in human ovarian carcinomas as defined by a monoclonal antibody, MLuC5. Eur J Cancer. 1996;32(9):1598–1602. doi:10.1016/0959-8049(96)00119-0
   Web of Science ®Google Scholar
• Song T, Choi CH, Cho YJ, Sung CO, Song SY, Kim T-J, Bae D-S, Lee J-W, Kim B-G. Expression of 67-kDa laminin receptor was associated with tumor progression and poor prognosis in epithelial ovarian cancer. Gynecol Oncol. 2012;125(2):427–432. doi:10.1016/j.ygyno.2012.01.030
   PubMed Web of Science ®Google Scholar
• Kuzuhara T, Suganuma M, Fujiki H. Green tea catechin as a chemical chaperone in cancer prevention. Cancer Lett. 2008;261(1):12–20. doi:10.1016/j.canlet.2007.10.037
   PubMed Web of Science ®Google Scholar
• Tabuchi M, Hayakawa S, Honda E, Ooshima K, Itoh T, Yoshida K, Park A-M, Higashino H, Isemura M, Munakata H, et al. Epigallocatechin-3-gallate suppresses transforming growth factor-beta signaling by interacting with the transforming growth factor-beta type II receptor. WJEM. 2013;3(4):100–107. doi:10.5493/wjem.v3.i4.100
   Google Scholar
• Huang S-F, Horng C-T, Hsieh Y-S, Hsieh Y-H, Chu S-C, Chen P-N. Epicatechin-3-gallate reverses TGF-β1-induced epithelial-to-mesenchymal transition and inhibits cell invasion and protease activities in human lung cancer cells. Food Chem Toxicol. 2016;94:1–10. doi:10.1016/j.fct.2016.05.009
   PubMed Web of Science ®Google Scholar
• Ko H, So Y, Jeon H, Jeong M-H, Choi H-K, Ryu S-H, Lee S-W, Yoon H-G, Choi K-C. TGF-β1-induced epithelial-mesenchymal transition and acetylation of Smad2 and Smad3 are negatively regulated by EGCG in human A549 lung cancer cells. Cancer Lett. 2013;335(1):205–213. doi:10.1016/j.canlet.2013.02.018
   PubMed Web of Science ®Google Scholar
• Liu L-C, Tsao TC-Y, Hsu S-R, Wang H-C, Tsai T-C, Kao J-Y, Way T-D. EGCG inhibits transforming growth factor-β-mediated epithelial-to-mesenchymal transition via the inhibition of Smad2 and Erk1/2 signaling pathways in nonsmall cell lung cancer cells. J Agric Food Chem. 2012;60(39):9863–9873. doi:10.1021/jf303690x
   PubMed Web of Science ®Google Scholar
• Annabi B, Lachambre M-P, Bousquet-Gagnon N, Pagé M, Gingras D, Béliveau R. Green tea polyphenol (-)-epigallocatechin 3-gallate inhibits MMP-2 secretion and MT1-MMP-driven migration in glioblastoma cells. Biochim Biophys Acta. 2002;1542(1–3):209–220. doi:10.1016/S0167-4889(01)00187-2
   PubMed Web of Science ®Google Scholar
• Hendrix MJ, Seftor EA, Kirschmann DA, Quaranta V, Seftor RE. Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann N Y Acad Sci. 2003;995(1):151–161. doi:10.1111/j.1749-6632.2003.tb03218.x
   PubMed Web of Science ®Google Scholar
• Nakano S, Megro S-i, Hase T, Suzuki T, Isemura M, Nakamura Y, Ito S. Computational molecular docking and X-ray crystallographic studies of catechins in new drug design strategies. Molecules (Basel, Switzerland). 2018;23(8):2020. doi:10.3390/molecules23082020
   PubMed Web of Science ®Google Scholar